Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0002874 (aplastic anemia)
 5,905 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Seventy-three consecutive patients with severe aplastic anemia were treated by marrow grafts from normal, HLA-identical siblings, and 68 lived long enough to demonstrate engraftment. In 21 patients the garft was rejected, and 19 of these patients died. This analysis, using a binary logistic regression model, was aimed at identifying factors that predicted marrow-graft rejection. Of the 24 factors entered into the analysis, only two strongly correlated with graft rejection: a positive relative response index in mixed leukocyte culture indicating sensitization of patient against donor (P less than 0.01); and a low number of marrow cells ( less than 3 X 10(8) cells per kilogram) used for transplantation (P less than 0.01). These findings suggest that more powerful immunosuppressive conditioning regimens should be used in patients who are sensitized, and that the greatest possible amount of donor marrow, perhaps supplemented by stem cells derived from the peripheral blood, should be obtained.
 ...
PMID:Marrow transplantation for treatment of aplastic anemia. An analysis of factors associated with graft rejection. 13 5

A patient suffering from aplastic anaemia was treated by bone-marrow transplantation from an ABO- and HLA-identical, MLC- and CML-negative, unrelated donor. MLC and CML became positive after transplantation indicating that a cellular immune response had developed against lymphocyte determinants not recognized prior to sensitization in vivo. Whether these determinants are governed by genes of the HLA region is unknown at present.
 ...
PMID:Education of lymphocytes in vivo following a transient take of a matched unrelated bone-marrow graft in man. 14 56

Bone marrow transplantation is a major therapeutic approach for treatment of patients with severe aplastic anemia or acute leukemia refractory to chemotherapy. It is possible only if an HLA matched sibing is found. ABO compatibility is not necessary. The conditionning regimen includes high doses of cyclophosphamide associated or not with a 1 000 rads total body irradiation. In acute leukemia, the two year percentage survival is 17%, in aplastic anemia it is 40%. Complications are immunologic : rejection, graft versus host disease and persistent severe immune deficiency.
 ...
PMID:[Allogenic bone marrow grafts (author's transl)]. 32 42

Aplastic anemia is a rare but usually fatal complication of gold salt therapy for rheumatoid arthritis. This report describes 3 patients who developed aplastic anemia while receiving gold salts, and a fourth patient who developed aplastic anemia after receiving gold and then cytotoxic agents. These patients failed to respond to conventional therapy for aplastic anemia and subsequently received bone marrow transplants from HLA-matched siblings. Engraftment occurred in all 4 patients. One patient is alive 2 years after transplantation, and 3 patients died of complications following transplantation.
 ...
PMID:Bone marrow transplantation in patients with gold-induced marrow aplasia. 32 60

The role of the ABO blood group system in determining the outcome of bone marrow transplantation was investigated in 53 patients with aplastic anemia and acute leukemia grafted from HLA-identical siblings. There was no correlation between ABO compatibility and marrow engraftment, graft rejection, or graft-versus-host disease. In 5 recipients with antibodies prior to transplantation to antigens of the ABH system present on the cells of their donors, plasma exchange and antibody absorption in vivo were effective in permitting engraftment of ABO-incompatible bone marrow. These findings indicate that the ABO system is not a clinically significant barrier to successful bone marrow transplantation in otherwise histocompatible individuals.
 ...
PMID:ABO blood group system and bone marrow transplantation. 32 17

23 patients with severe aplastic anemia have been treated. 10 marrow grafts between HLA matched siblings were performed after conditioning with cyclophosphamide. 5 are still alive at over 7 months to over 2 1/2 years after grafting. 3 are hemopoietic chimeras and 2 show autologous marrow reconstitution. 13 patients were treated by ALG with or without transfusion of allogeneic marrow. 9 are still alive with partial to complete autologous hemopoietic reconstitution at over 1 month to over 4 years. It is concluded that in many instances aplastic anemia is an autoimmune disease rather than a primary failure of the hemopoietic stem cells. In acute leukemia allogeneic marrow grafts still pose enormous problems and only one of our 12 grafts has become a longterm survivor.
 ...
PMID:[Allogenic bone marrow transplantation in severe aplastic anemia and refractory acute leukemia. 35 cases]. 33 3

Bone marrow transplantation using an HLA-MLC-identical sibling is the most valuable treatment of severe aplastic anemia.2,6,7 Between November 1973 and March 1977, 25 consecutive patients have been treated by marrow transplantation in our unit. Nine patients are alive with complete hematologic restoration between 3 months and 3 years. The high mortality can be largely accounted for by marrow graft rejection (14 patients). Despite the small number of patients, we have tried to identify prognostic factors associated with marrow graft rejection. They are mainly the existence of anti-HLA antibodies, the sex difference, and the normal PHA and MLC response before grafting. After the graft, the disappearance of anti-HLA antibodies has a good prognostic value. The appearance of autolymphocytotoxins seems to correlate strongly either with rejection or graft-versus-host disease.
 ...
PMID:Allogeneic bone marrow transplantation in aplastic anemia--report of 25 cases. 34 52

In a series of 30 bone marrow grafts (in 29 recipients) from HLA-identical siblings for aplastic anemia, no correlation was demonstrated between rejection and pregraft HLA antibodies (P greater than 0.50). However, after grafting, HLA antibodies persisted in nine cases and graft rejection occurred, whereas in all but one of the remaining eight cases the HLA antibodies disappeared and a permanent engraftment was observed (P = 0.0008). These results suggest a relationship between engraftment and persistence or disappearance of HLA antibodies as an indication of the level of immunosuppression obtained with the conditioning regimen.
 ...
PMID:Lymphocytotoxic antibodies and bone marrow grafts from HLA-identical siblings. I. HLA antibodies. 36 May 32

Four patients with acute leukemia and one with aplastic anemia were not transfused within 90 days before marrow transplantation from the HLA-identical sibling. When studied 4 to 12 1/2 months after transplantation their immunoglobulin allotypes were those of their donors.
 ...
PMID:Immunoglobulin production of donor origin after marrow transplantation for acute leukemia or aplastic anemia. 36 25

Ninety multitransfused patients with severe aplastic anemia were conditioned with cyclophosphamide and given marrow transplants from HLA-identical siblings. Thirty patients had complement-dependent lymphocytotoxins against a panel of cells from unrelated individuals immediately before transplantation while 60 did not. Lymphocytotoxins were more frequent among patients who had received more blood product transfusions, and these patients were more likely to be refractory to random platelet support. Twenty-seven patients rejected the marrow transplant while 63 had sustained engraftment. The present of pretransplant lymphocytotoxins did not correlate with graft rejection and hence does not appear to be useful as a test for identification of patients at high risk of rejection.
 ...
PMID:Pretransplant lymphocytotoxins do not predict bone marrow graft rejection. 36 28


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>